Skip to content

PTSD research published in 2026

Page 4 of 6: studies 61 to 80 of 118, newest first. Back to the PTSD overview

Studies

Toward Integrating Intranasal Esketamine with Traumatic-Memory Psychotherapy in Treatment-Resistant Depression: A Narrative Review and Feasibility-Oriented Protocol Proposal.

Behavioral Sciences May 14, 2026 Fabiola Raffone, Carlo Ignazio Cattaneo, Enrico Pessina et al.

Trauma-related autobiographical memories can manifest as involuntary, vivid, emotionally charged intrusions that perpetuate avoidance, negative emotions, and functional impairment. While these memories are central to post-traumatic stress disorder (PTSD), they also occur across diagnoses and are often reported in depressive disorders, including treatment-resistant depression (TRD). Although...

R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential.

ACS Chemical Neuroscience May 6, 2026 Maxemiliano V. Vargas, Cassandra J. Hatzipantelis, Lee E. Dunlap et al.

Recent clinical evidence suggests that racemic 3,4-methylenedioxymethamphetamine (MDMA) might be useful for treating a range of neuropsychiatric diseases including post-traumatic stress disorder (PTSD) and depression. However, concerns about its abuse potential stemming from its monoamine releasing properties have hampered its clinical development. Thus, safer analogues of racemic MDMA with...

Effectiveness of guided imagery to improve sleep quality among young adults with post-traumatic stress disorder (PTSD)

Journal of Associated Medical Sciences May 2, 2026 G Vikraman, Benitta Paulin Giftlin R.

Background: Post-traumatic stress disorder often leads to ongoing sleep difficulties such as insomnia and nightmares, which can interfere with mood, concentration, and daily activities. Guided imagery, a relaxation method that uses calming, multisensory visualizations, has shown potential to improve sleep and reduce distress in people experiencing high stress or trauma. This study evaluates the...

1056 Targeted Dream Incubation’s Impact on Dream Self-Efficacy, Nightmares, Suicide, PTSD, and Insomnia

Sleep May 1, 2026 Westley Youngren, Victoria West Staples, Emma Angle et al.

Abstract Introduction Targeted Dream Incubation (TDI) is the process of giving an individual auditory cues (i.e., “think of a tree”) while they are falling asleep, with the goal of shaping dream content (into something such as a tree). Recent research has demonstrated TDI may be able to increase dream self-efficacy (DSE) and influence other mental health outcomes. Thus, our study explored how...

0123 Large Language Model-Derived Dream Affect is a Prospective Predictor of PTSD Symptoms in Hospitalized Trauma Patients

Sleep May 1, 2026 Holland Doise, A. Gonzalez Quesada, Garrett Baber et al.

Abstract Introduction Nightmares are associated with more severe posttraumatic stress disorder (PTSD). The advent of large language models (LLM) offers unique advantages to efficiently code affective dream content over human methods, which can be resource intensive and prone to error. This study tested whether dream affect (DA), measured via self-report, human-rated narrative coding, and LLM...

Longitudinal Outcomes of Oral Glutamatergic Augmentation in Trauma-Related Dissociation: A Six-Month Case Study.

Cureus May 1, 2026 Ngo Cheung

Trauma-related dissociation can present with derealisation, depersonalisation, abrupt lapses in awareness, memory gaps, and fugue-like states, and it may be difficult to treat with standard approaches alone. Glutamatergic interventions have been proposed as neuroplasticity-focused strategies because N-methyl-D-aspartate (NMDA) receptor antagonism and downstream...

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial.

JAMA Psychiatry May 1, 2026 Amanda Jones, Jennifer Warner-Schmidt, Hannah Kwak et al. 6 citations

The phase 2 data presented here support the development of TSND-201 for posttraumatic stress disorder (PTSD), a disorder for which there is a significant unmet need for rapid-acting and effective treatments. TSND-201 (methylone) is a highly selective, rapid-acting neuroplastogen that releases serotonin, norepinephrine, and dopamine without direct activity at 5-hydroxytryptamine (5-HT) 2A...

Methylone demonstrates improvement in PTSD symptoms in Phase 2 study

The Brown University Psychopharmacology Update April 30, 2026

Four weekly doses of TSND‐201 (methylone), an analog of 3,4 methylenedioxymethamphetamine (MDMA), resulted in significant improvement relative to placebo in reducing symptoms of post‐traumatic stress disorder (PTSD), a Phase 2 study has found. Treatment‐emergent adverse events associated with TSND‐201 were generally mild to moderate in severity, with no significant suicidal ideation. Study...

DOI: 10.1002/pu.31448 (opens in new tab) Placebo Adverse effect Phase matter Posttraumatic stress +1

Assessing Sleep Disturbance in PTSD: Nightmares, Awakenings, and Sleep Terrors

April 28, 2026 David Osser

When assessing sleep disturbances in PTSD, count disturbed awakenings as nightmares at baseline. This is a key symptom of PTSD-related sleep problems and a target for treatment. Investigate nicotine withdrawal in pack-a-day smokers who awaken after several hours. An important indicator is the patient’s ability to return to sleep after smoking a cigarette. For sleep terrors with thrashing and...

Media hype regarding psychedelic treatments for depression and PTSD from 2017 to 2024

Scientific Reports April 25, 2026 Audrey G. Evers, Elizabeth C. Stade, Aadesh Salecha et al. 1 citation

Enthusiastic media coverage of psychedelics as a treatment for mental health disorders is perceived as hyped compared to coverage of established treatments. To measure potential hype, we conducted pre-registered analyses comparing media coverage (e.g., newspaper articles) of psychedelics to FDA-approved antidepressants for major depressive disorder and posttraumatic stress disorder. We used...

DOI: 10.1038/s41598-026-50186-x (opens in new tab) Full text (opens in new tab) Anxiety Depression economics Media coverage Mental health +9

REDUCTION IN SYMPTOMS OF POSTTRAUMATIC STRESS DISORDER AND DEPRESSION IN UKRAINIAN REFUGEES PRACTICING TRANSCENDENTAL MEDITATION

Clinical and Preventive Medicine April 20, 2026 Mykola Didukh, K. Freytag, Vitalii Lunov et al.

Introduction. Following the full-scale Russian invasion of Ukraine, there has been a substantial increase in the need for accessible, rapid-acting, and non-pharmacological approaches to alleviate symptoms of post-traumatic stress disorder and depression among Ukrainian refugees. One potentially useful intervention is the Transcendental Meditation program. Aim. To assess the effectiveness of the...

DOI: 10.31612/2616-4868.2.2026.07 (opens in new tab) Major depressive disorder Transcendental meditation Depression economics Intervention counseling +5

Effect of brief online mindfulness-based cognitive therapy in patients with digital replantation: a study protocol for a randomized controlled trial.

Trials April 13, 2026 Fanshan Huang, Weiwei Wang, Xin Miao et al.

Traumatic amputations are common traumatic injuries that require digital replantation to restore the form, function, and sensation of the hand. The post-surgical survival of replanted digits is influenced by multiple factors, including psychological factors such as posttraumatic stress disorder (PTSD), anxiety, and depression. Mindfulness-based cognitive therapy (MBCT) is considered a potential...

DOI: 10.1186/s13063-026-09697-1 (opens in new tab) Full text (opens in new tab) PTSD Digital replantation Mindfulness-based cognitive therapy Randomized controlled trial +1

[Impact of physical activity and meditation on the clinical improvement of military personnel suffering from post-traumatic stress disorder: Focus on the role of attachment style and professional reintegration].

L'Encephale April 7, 2026 Déborah Eymond, Alyson Miquel, Anais Duffaud et al.

Military personnel are frequently exposed to traumatic situations that can lead to chronic post-traumatic stress disorder (PTSD). PTSD complicates their reintegration due to the high risk of retraumatization. To support the reintegration of injured servicemen and women, the army has developed the Omega program which includes courses at the Centre des Blessés de l'Armée de Terre (CReBAT). These...

Are there any significant adverse effects associated with the use of psychedelic-assisted therapy in patients with post-traumatic stress disorder (PTSD)?

Zenodo (CERN European Organization for Nuclear Research) April 7, 2026 preprint

Psychedelic-assisted therapy for PTSD tends to produce mild, transient adverse effects, but concerns about long-term safety and inconsistent reporting of adverse events highlight the need for further research.

DOI: 10.5281/zenodo.19453257 (opens in new tab) Adverse effect Incidence geometry Stress linguistics Clinical trial +2

Biomarkers for complex post-traumatic stress disorder: translational and evolutionary perspectives

Frontiers in Psychiatry April 7, 2026 Ravi Philip Rajkumar

Post-traumatic stress disorder (PTSD) is a chronic mental illness that occurs following exposure to traumatic stressors such as combat, disasters, or assault. It is characterized by a triad of reexperiencing of the trauma, avoidance of triggers for such recollections, and increased vigilance towards threats (1). In 1992, Judith Herman described a variant of PTSD that occurred in persons who had...

Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series.

European Journal of Psychotraumatology April 1, 2026 Maud Rothärmel, Lila Mekaoui, François Kazour et al. 1 citation

Background: Posttraumatic stress disorder (PTSD) is a severe and frequent affection that is highly comorbid to major depressive disorder. Comorbid PTSD and depression increase the risk of treatment-resistant depression (TRD), with a high risk of functional impairment and suicide. Esketamine nasal spray is a recent validated treatment for TRD, but its efficacy on comorbid TRD-PTSD remains...

Mindfulness-Based Intervention to Lower Post-Traumatic Stress Disorder in Survivors of Domestic Violence

Gadjah Mada Journal of Professional Psychology March 30, 2026 Vincent Eddy Kuncoro Hartono, Nida Ul Hasanat

This study aimed to reduce post-traumatic stress disorder (PTSD) levels in survivors of domestic violence (DV) through a mindfulness-based intervention program modified from Brief Mindfulness-Based Stress Reduction (BMBSR) and Mindfulness-Based Distress Management Training. Seven female DV survivors were involved in the program, which consisted of six meetings over three weeks. The participants...

Trauma, Possession, and PTSD: Exploring Nogitsune Arc in MTV’s Teen Wolf

ILN Journal: Indian Literary Narratives. March 30, 2026 Amisha Bharat Jayakar, Dr Ashok Ghuge

As a genre, supernatural teen television often engages with complex psychological themes pertaining to adolescents and their lives. One such show is MTV’s Teen Wolf (2011), centered around Scott McCall, a teenager coming to terms with his recent transformation into a werewolf. Teen Wolf, specifically Season Three, Part Two, exhibits these aspects, focusing on trauma using the background of...

DOI: 10.70396/ilnjournal.v3n1.a.10 (opens in new tab) Arc geometry Population Field mathematics Noise video

Underlying Mechanisms of the Treatment Efficacy of (R, S)‐Ketamine for Post‐Traumatic Stress Disorder and Depression: A Review

Medicine Advances March 27, 2026 Thomas Edward Cutting, Richard Evans Hartman

ABSTRACT Numerous studies have demonstrated the efficacy of (R, S)‐ketamine as a treatment for post‐traumatic stress disorder (PTSD), treatment‐resistant depression, and comorbid occurrences of these conditions. The (R) and (S) stereoisomers of ketamine have also demonstrated efficacy in attenuating stress and depressive symptoms, with (R)‐ketamine demonstrating reduced abuse potential and side...

DOI: 10.1002/med4.70051 (opens in new tab) Full text (opens in new tab) Anxiety‐like behavior Depressive‐like behavior Learned fear Post‐traumatic stress disorder +2

A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD

medRxiv Preprint Server March 27, 2026 Brooke L. Sevchik, S. Parker Singleton, Analiese Lahey et al. preprint

3,4-methylenedioxymethamphetamine (MDMA) has emerged as a potential treatment for post-traumatic stress disorder (PTSD), generating considerable enthusiasm in the field. However, rapidly changing evidence in a fast-moving field can be challenging to integrate. Here, we present a living systematic review and open-data meta-analytic resource on MDMA treatment for PTSD. In this initial release,...